Agreement
Genmab Signs Agreement with Janssen for Next-Generation CD38 Antibody, HexaBody®-CD38
Genmab
PR-M06-19-NI-007Jun 12, 2019
Drug Development
Janssen Submits Application to U.S. FDA Seeking Approval of ERLEADA® (apalutamide) for Patients with Metastatic Castration-Sensitive Prostate Cance
Janssen Pharmaceutical Companies
PR-M05-19-NI-001May 01, 2019
FDA Approval
U.S. FDA Approves DARZALEX® (daratumumab) Split-Dosing Regimen
Janssen Pharmaceutical Companies
PR-M02-19-NI-028Feb 13, 2019
Phase 3
New DARZALEX® (daratumumab) Phase 3 Study Shows Efficacy and Safety Data of Anti-CD38 Monoclonal Antibody in Patients with Newly Diagnosed Multiple Myeloma
Janssen Pharmaceutical Companies
PR-M12-18-NI-019Dec 06, 2018
Depression
New Data Presented at Psych Congress 2018 Sheds Light on the Significant Economic Burden of Treatment-Resistant Depression Amongst U.S. Veterans
Janssen Pharmaceutical Companies
PR-M10-18-NI-104Oct 30, 2018
Clinical Data
Janssen Announces New Three-Year TREMFYA® (Guselkumab) Data Demonstrates Stably Maintained Rates of Skin Clearance in Patients with Moderate to Severe Plaque Psoriasis
Janssen Pharmaceutical Companies
PR-M10-18-NI-073Oct 22, 2018
RNA
Janssen Collaborates on RNA Therapy
Nice Insight
PAO-M10-18-NI-008Oct 11, 2018
New Drug Application
Janssen Submits New Drug Application to U.S. FDA Seeking Approval of Erdafitinib for the Treatment of Metastatic Urothelial Cancer
Janssen Pharmaceutical Companies
PR-M09-18-NI-083Sep 26, 2018
Study Results
Janssen Reports Positive Topline Results for ATLAS Phase III Study of a Novel, Long Acting Injectable Two-Drug Regimen for the Treatment of HIV-1
Janssen Pharmaceutical Companies
PR-M09-18-NI-045Sep 17, 2018
Regulatory
Janssen Submits U.S. & EU Regulatory Applications Seeking Approval of DARZALEX® (daratumumab) Split Dosing Regimen
Janssen Pharmaceutical Companies
PR-M08-18-NI-093Aug 23, 2018
Positive Opinion
Janssen Receives Positive CHMP Opinion for Darzalex®▼ (daratumumab) as Frontline Treatment for Newly Diagnosed Patients with Multiple Myeloma
Janssen Pharmaceutical Companies
PR-M08-18-NI-007Aug 02, 2018
FDA Approval
Janssen Announces U.S. FDA Approval of SYMTUZA™ (D/C/F/TAF), the First and Only Complete Darunavir-Based Single-Tablet Regimen for the Treatment of HIV-1 Infection
Janssen Pharmaceutical Companies
PR-M07-18-NI-061Jul 19, 2018
Janssen Announces Initiation of Phase 1b/2 Clinical Development Program Evaluating JNJ-68284528 CAR-T Cells for the Treatment of Multiple Myeloma
Janssen Pharmaceutical Companies
PR-M06-18-NI-005Jun 01, 2018
Real-World Study
New Real-World Study Finds Long-Term XARELTO® (rivaroxaban) Use Resulted in Fewer Strokes and Systemic Emboli
Janssen Pharmaceutical Companies
PR-M05-18-NI-101May 28, 2018
Commission Approval
Janssen Announces European Commission Approval of JULUCA®▼ (dolutegravir/rilpivirine), the First Two-Drug Regimen, Once-Daily, Single-Pill for the Treatment of HIV-1
Janssen Pharmaceutical Companies
PR-M05-18-NI-088May 23, 2018
Data Presentation
Janssen to Present Data in Treatment-Resistant Mental Ilnesses
Janssen Pharmaceutical Companies
PR-M05-18-NI-029May 08, 2018
Acquisition
Janssen to Acquire BeneVir Biopharm to Advance Immunotherapy Regimens
Janssen Pharmaceutical Companies
PR-M05-18-NI-021May 07, 2018
Study
Real-World Study Shows INVOKANA® (canagliflozin) 300mg Demonstrates Better Blood Glucose Control Than Farxiga® (dapagliflozin) 10mg in Patients with Type 2 Diabetes
Janssen Pharmaceutical Companies
PR-M05-18-NI-010May 02, 2018
Cardiovascular
Janssen Announces Worldwide Development and Commercialization Collaboration with Bristol-Myers Squibb to Advance a Next-Generation Therapy for Cardiovascular Diseases
Janssen Pharmaceutical Companies
PR-M04-18-NI-72Apr 20, 2018
Biologics
Next Generation Biologics, Janssen's Tremfya, Eli Lilly's Taltz, and Novartis' Cosentyx, Raising the Bar in Psoriasis Management
Spherix Global Insights
PR-M03-18-NI-040Mar 12, 2018